Study of SKB518 for advanced gynecologic cancers
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of gynecologic cancer (ovarian, fallopian tube, primary peritoneal, cervical, or endometrial) that has been confirmed by a biopsy or tissue sample.
- You have had between 1 and 4 prior cancer treatments (depending on the exact group), and if you have ovarian cancer with a BRCA gene change, you must have tried a PARP inhibitor like olaparib.
- You can still do most daily activities (ECOG 0 or 1) and your life expectancy is at least 12 weeks.
- You have not been treated with irinotecan or topotecan before, and you are not pregnant or breastfeeding.
- Your organ function (kidney, liver, bone marrow) and heart pump function meet lab values required by the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SKB571 in people with stomach, intestinal, or related cancers. The goal is to see if it can shrink tumors and help patients live longer.
This trial tests a new drug called SKB518 for people with advanced solid tumors that have stopped responding to standard treatments or cannot receive them. The goal is to see if SKB518 can help shrink or control the tumor.
This study tests a new drug called SKB118 for advanced solid cancers (any cancer that has spread) that have not responded to standard treatments. The drug is designed to help the immune system fight cancer cells.
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
This study tests SKB565, a new injectable cancer treatment, in people with advanced solid tumors (cancer that has spread or hasn't responded to standard treatments). The trial aims to find the right dose and learn how well it works.
This trial tests a new drug called SKB103 for people with advanced solid tumors that have not responded to standard treatments or who cannot tolerate them. The study aims to see if SKB103 is safe and effective.
Hear when a new Advanced Gynecological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.